428 related articles for article (PubMed ID: 32364296)
21. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis.
Gooderham MJ; Lynde C; Turchin I; Avadisian M; Labelle M; Papp KA
J Dermatol; 2022 Jan; 49(1):95-105. PubMed ID: 34747071
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
[TBL] [Abstract][Full Text] [Related]
23. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
24. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
Reich A; Pinter A; Maul JT; Vender RB; Torres T; Brnabic A; Haustrup N; Reed C; Schuster C; Riedl E
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
[TBL] [Abstract][Full Text] [Related]
25. Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry.
McLean RR; Sima AP; Beaty S; Low R; Spitzer RL; Stark JL; Lesser E; Lee E; Armstrong A
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2739-2751. PubMed ID: 37755689
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
Galluzzo M; Talamonti M; De Simone C; D'Adamio S; Moretta G; Tambone S; Caldarola G; Fargnoli MC; Peris K; Bianchi L
Expert Opin Biol Ther; 2018 Jul; 18(7):727-735. PubMed ID: 29798698
[TBL] [Abstract][Full Text] [Related]
27. Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.
Gkalpakiotis S; Kojanová M; Fialová J; Cetkovská P; Vašků V; Vantuchová Y; Machovcová A; Gkalpakioti P; Hrdá P; Arenberger P
Dermatol Ther (Heidelb); 2024 Jan; 14(1):115-130. PubMed ID: 38032433
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
[TBL] [Abstract][Full Text] [Related]
29. Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Vender RB; Lynde CW
J Cutan Med Surg; 2022; 26(3):267-273. PubMed ID: 35134313
[TBL] [Abstract][Full Text] [Related]
30. Psoriasis patients' characteristics associated with high PASI response to tildrakizumab: an international dual center study.
Burlando M; Maul JT; Salvi I; Simic D; Cozzani E; Ak M; Birkenmaier I; Parodi A
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6772-6776. PubMed ID: 36196725
[TBL] [Abstract][Full Text] [Related]
31. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
[TBL] [Abstract][Full Text] [Related]
32. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
34. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
35. Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study.
Pinter A; Soliman AM; Pivneva I; Ghanbariamin R; Yang M; Truong B; Puig L; Lebwohl M
Dermatol Ther (Heidelb); 2024 May; 14(5):1259-1271. PubMed ID: 38727996
[TBL] [Abstract][Full Text] [Related]
36. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
37. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
38. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.
Strober B; Patil D; McLean RR; Moore-Clingenpeel M; Guo N; Levi E; Lebwohl M
J Dermatolog Treat; 2022 Dec; 33(8):3178-3187. PubMed ID: 36026543
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M; Gargiulo L; Ibba L; Malagoli P; Amoruso F; Balato A; Bardazzi F; Burlando M; Carrera CG; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Travaglini M; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1649-1657. PubMed ID: 38748344
[TBL] [Abstract][Full Text] [Related]
40. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM).
Sbidian E; Mezzarobba M; Weill A; Coste J; Rudant J
Br J Dermatol; 2019 Jan; 180(1):86-93. PubMed ID: 29791721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]